NCT01397591View on ClinicalTrials.gov

Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2013

Conditions
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell Lymphoma
Interventions
BIOLOGICAL

Ofatumumab

Given intravenously

DRUG

Bortezomib

Given intravenously

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER

NCT01397591 - Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter